Advertisement
Latest News
- Private clinic delivers Sweden’s first Leqembi treatment
- Pharmaceutical giants warn: Europe is losing investment
- Health economist after TLV’s assessment: Kisunla still has a chance
- Disruptive sells former Guard platform – deal ‘not financially material’
- TLV on Kisunla: High cost, high uncertainty
- Intuitive's da Vinci 5 receives CE marking for cardiac surgery
- Changing jobs in the Nordics? Avoid this common mistake
- Petter Hartman: “Who dares to be the first customer for innovation?”
- Trump calls for major change to childhood vaccines
- Billion‑dollar merger forms a radiopharmaceutical heavyweight
- US lawsuits target GLP‑1 manufacturers over alleged link to vision damage
- “Considerable anxiety” at Mölnlycke as 150 jobs face cuts
- 12 new medicines recommended for EU approval
- Staffing questions remain as Mölnlycke prepares to split
- FDA clears 3.95 million dollar gene therapy
- Pepaxti gets regulatory boost – Oncopeptides shares jump
- Sciety names new CEO to succeed co-founder
- Novartis expands brain‑delivery push with Sironax deal
- Novo Nordisk enters billion-dollar collaboration with Orbis Medicines
- A new name for a broader outlook
- Stem cell setback in infant heart condition
- Bavarian Nordic names Tarja Stenvall new CEO
- Rarity Bioscience targets hidden disease signal with new test
- Mölnlycke to split into two companies
- Novo partners with AI giant
- 17 companies receive millions from BII: “We are facing a historic opportunity”
- Sanofi to transfer 20 medicines to Cheplapharm
- Axoltis moves ALS drug forward after encouraging clinical findings
- David Lang on the future of robotic surgery: More people should gain access
- Novo walks away from Ascendis GLP‑1 partnership
- Lilly is sanctioned for remarks to Swedish media
- Ambu acquires US endoscopy company
- FDA approves first SMA therapy targeting muscle loss
- Tataa is acquired by a Dutch firm
- GSK to close German vaccine plant – 641 jobs at risk
- Tandem Health raises $100m to expand in Europe
- Etcamah misses main goal after recent FDA approval
- Danish pharma giant shortens name – becomes Novo
- More details emerge about QuantumCell’s operational team
- Two nordic paths to fewer RSV admissions
- Alzinova strengthens its cash position ahead of Phase II study
- US boost for Lundbeck’s Cushing’s drug candidate
- Sectra scales up in Denmark’s new eastern region
- Getinge aims to expand in transplantation – with an eye on China
- CordenPharma targets 500m injectable units with €80m expansion
- Marie Gårdmark: Are FDA and EMA drifting apart?
- How SweTrial aims to bring more clinical trials to Sweden
- Artisan Partners demands board changes at Novartis after share-price plunge
- Breakthroughs in narcolepsy recognized by Lasker Awards
- Novonesis to invest €600 million in India factory
- Sobi gains regulatory momentum with new FDA Fast Track designation
- AddLife adds new company to its portfolio
- Denmark a leader in EU clinical trials: “We should never accept unnecessary delays”
- Elizabeth Schepke named Childhood cancer researcher of the Year 2026
- Bangladesh was close to eliminating measles – now it has the world’s largest outbreak
- SmartCella secures key patents in the US and Japan
- Regulatory milestone strengthens Xinnate’s EB program
- Nordic newcomer on an acquisition drive – snaps up four Swedish distributors
- Novo Nordisk Pharmatech CEO to step down
- Novartis hit by another major setback – shares plunge
- BII injects fresh millions into six ‘promising’ Danish startups
- Political consensus on how to bring more new medicines to Sweden
- Novo Nordisk halts two more heart drug trials
- Four in ten children shed obesity in Novo trial
- “Not the results we hoped for” – Novartis’ heart study shows no benefit
- FDA Breakthrough Device Designation lifts Neola shares
- Astra Zeneca receives US approval for Etcamah
- Dialysis company hit with $15M bill after massive patient data breach
- Sweden takes new steps to tackle oestrogen shortages
- Lithuania accelerates life science ambitions with major cell therapy investment
- BII and GU Ventures collaborate on oligonucleotide project
- AbbVie’s myeloma candidate hits both goals in Phase III
- She will lead Unilabs in the Nordics
- IRLAB CEO to step down
- Novartis reshapes biologics business – 130 jobs at risk
- Chinese approval for Leqembi auto-injector
- A turning point for personalized cancer vaccines – ”The field is moving quickly now”
- Swedish‑developed CT scanner cleared in Europe: “Very exciting”
- The newborn injection more parents are choosing to decline
- BTK inhibitor shows efficacy in MS – without liver toxicity
- Norwegian drug developer expands into other Scandinavian markets
- Orexo CEO on settlement: “Very mixed feelings”
- Fatal immune events spur trial pauses at Novartis and BMS
- AstraZeneca combination shows promise in advanced lung cancer
- Medtronic issues second recall after 184 serious patient injuries
- Sweden appoints its first professor of HTA
- Canada backs reimbursement for BioArctic’s Leqembi
- Eli Lilly to acquire Merida Biosciences for up to 2.9 billion dollars
- Elekta secures €100 million loan from EIB
- Aqilion could be up for sale after receiving an indicative offer
- Lifecare acquires 80 percent of Ocean TuniCell
- “If we can’t import it, we want to make it ourselves”
- U.S. patent clears path for Elicera’s glioblastoma CAR‑T
- GSK’s potential blockbuster makes Swedish comeback
- FDA OKs new once-daily HIV combo pill
- Nykode raises NOK 286m to accelerate drug development
Advertisement
Advertisement
Advertisement
News from our members
- Your UKRP Partner for Medical Device Market Access in the UK
- Kostnadseffektiv och driftsäker nivåmätning med Rosemount 1208
- Medical Device Software Process Design: Why IEC 62304 Matters
- Kostnadseffektiv automation för framtidens företag
- Your Partner for Clinical Study Submissions and Regulatory Interactions
Most read
Advertisement
Advertisement
BREAKING